|Bid||87.52 x 1200|
|Ask||88.08 x 1800|
|Day's Range||87.45 - 89.17|
|52 Week Range||74.13 - 147.17|
|PE Ratio (TTM)||24.39|
|Earnings Date||Oct 24, 2018 - Oct 29, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||112.46|
Most of the buy-and-hold crowd tends to steer clear of biotech stocks, and for good reason. Biotechnology companies can be uncomfortably risky. Far too many horror stories of failed drug trials or the expiration of a crucial patent leading to massive stock plunges have circulated for years now, souring would-be buyers on the entire industry. However, conclusions based on a handful of biotech stocks may have erroneously prevented investors from plugging into a perfectly reasonable risk-reward relationship. Said differently: Not all biotech stocks turn into disasters. The industry as a group is up nearly 70% for the past five years, proving many of these companies can reward patient shareholders who choose wisely. It's simply a matter of doing your homework and having a little common sense. Here are seven biotech stocks that aren't nearly as risky as their typical peer. Thus, they may have a place in more risk-averse portfolios than most investors might presume. SEE ALSO: The 25 Best Stocks to Buy (According to Hedge Funds)
The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Celgene, Sanofi and Gilead Sciences
Now that the biotechnology sector is well on its way to bouncing back after bottoming in May 2018, investors may feel like they missed out. The fears that previously plagued biotech stocks are no longer as big a threat. The government is no longer putting companies hiking drug price in their cross-hairs, at least not for now. This favorable environment should help biotech firms carry out their plans for the rest of the year.
Pipeline updates and data read-outs at the 27th European Academy of Dermatology and Venereology (EADV) Congress in France comprise some of the key developments in the biotech sector this week.
(Note:The author of this fundamental analysis is a financial writer and portfolio manager. He and his clients own shares of CELG.) Celgene's Corp.'s ( CELG) stock has fallen by almost 16% so far in 2018.
The healthcare industry is watching the Trump presidency closely. President Trump's promise to repeal and replace Obamacare hit repeated stumbling blocks in Congress. Despite the uncertainty surrounding these efforts to overhaul the nation's healthcare system, a number of healthcare stocks rose dramatically throughout 2017.
U.S. Senator Bob Menendez’s latest re-election television advertisement steps up the attack on his Republican challenger, former Celgene Corp. chief executive Bob Hugin, for a $280 million legal settlement ...
HENDERSON, NV / ACCESSWIRE / September 12, 2018 / Immuno Oncology has been getting investors revved up in 2018. Abpro and Neon announced IPOs and recently, German biotech Affimed agreed to an alliance with Roche's Genentech to discover new cancer immunotherapies with an amazing $5 billion dollar deal. Roche is not the only major player in Immuno Oncology, and you can bet their competition is working to make their own splash announcements in the coming months.
Celgene Corporation (CELG) today announced the results of two post hoc sub-analyses of clinical trials for OTEZLA® (apremilast) at the 27th European Academy of Dermatology and Venereology (EADV) Congress in Paris, France. Findings suggest OTEZLA offered meaningful improvements in outcomes important to patients with moderate to severe plaque psoriasis, which may not be captured by common measures of treatment efficacy that focus only on skin clearance, such as Psoriasis Area Severity Index (PASI) 75.
177Lu-PSMA-617, a prostate specific membrane antigen-targeted radioligand therapy, is Endocyte's (ECYT) lead program. It is being evaluated in a phase III study for mCRPC for PSMA-positive patients
In the second quarter, Editas Medicine (EDIT) reported revenues of $7.3 million from collaborations and other R&D (research and development) activities. In comparison, the company’s revenues reached $3.1 million in the second quarter of 2017.
Revlimid is Celgene's biggest moneymaker by far. But here's how and why CEO Mark Alles wants to make it disappear.
The best biotech companies to invest in tend to have a commonality: A strong streak of earnings growth.